FV-100: antiviral; potent and selective inhibitors of varicella zoster virus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71587897 |
| CHEMBL ID | 4297380 |
| MeSH ID | M0518593 |
| Synonym |
|---|
| fv-100 |
| 956483-03-7 |
| l4n5f436fo , |
| unii-l4n5f436fo |
| l-valine, 5'-ester with 3-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo(2,3-d)pyrimidin-2(3h)-one hydrochloride |
| valnivudine hydrochloride |
| fv100 |
| DTXSID40241910 |
| Q27282701 |
| CHEMBL4297380 |
| (s)-((2r,3s,5r)-3-hydroxy-5-(2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3(2h)-yl)tetrahydrofuran-2-yl)methyl 2-amino-3-methylbutanoate hydrochloride |
| CS-0017004 |
| HY-19856 |
| AKOS040758494 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters for the elderly subjects were comparable to those for the younger subjects." | ( Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Atiee, G; Boehlecke, B; Henson, GW; Hutchins, JT; Matson, M; Morris, A; Patti, JM; Pentikis, HS, 2011) | 0.37 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the very low water solubility of this compound gave poor oral bioavailability (approximately 14%)." | ( Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. Adak, R; Andrei, G; Balzarini, J; Camarasa, MJ; Díez-Torrubia, A; Henson, G; Jones, AT; Luoni, G; McGuigan, C; Migliore, M; Naesens, L; Pathirana, RN; Sienaert, R; Snoeck, R; Velázquez, S; Verbeken, E, 2007) | 0.34 |
| " The Cf1743 compound has proved to be significantly more potent than all reference anti-VZV compounds, as measured either by inhibition of infectious virus particles and/or viral DNA production; however, the high lipophilicity and very low water solubility of this compound gives poor oral bioavailability (<14%)." | ( FV-100: the most potent and selective anti-varicella zoster virus agent reported to date. Migliore, M, 2010) | 0.36 |
| "The bicyclic nucleoside analogue (BCNA) Cf1743 and its orally bioavailable prodrug FV-100 have unique potential as varicella-zoster virus (VZV) inhibitors to treat herpes zoster (shingles) and the therewith associated pain, including post-herpetic neuralgia (PHN)." | ( FV-100 for the Treatment of Varicella-Virus (VZV) Infections: Quo Vadis? De Clercq, E, 2022) | 0.72 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Oral dosing in rodents and preliminary pharmacokinetics assessment was made, followed by an exploration of alternative formulations and the preparation of pro-drugs." | ( Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. Adak, R; Andrei, G; Balzarini, J; Camarasa, MJ; Díez-Torrubia, A; Henson, G; Jones, AT; Luoni, G; McGuigan, C; Migliore, M; Naesens, L; Pathirana, RN; Sienaert, R; Snoeck, R; Velázquez, S; Verbeken, E, 2007) | 0.34 |
| " To characterize the pharmacokinetics and safety of oral FV-100, 3 randomized, double-blind, placebo-controlled clinical trials were conducted: (i) a single-ascending-dose study in 32 healthy subjects aged 18 to 55 years (100-, 200-, 400-, and 800-mg doses) with an evaluation of the food effect in the 400-mg group; (ii) a multiple-ascending-dose study in 48 subjects aged 18 to 55 years (100 mg once daily [QD], 200 mg QD, 400 mg QD, 400 mg twice a day, and 800 mg QD for 7 days); and (iii) a 2-part study in subjects aged 65 years and older with a single 400-mg dose in 15 subjects and a 400-mg QD dosing regimen for 7 days in 12 subjects." | ( Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Atiee, G; Boehlecke, B; Henson, GW; Hutchins, JT; Matson, M; Morris, A; Patti, JM; Pentikis, HS, 2011) | 0.37 |
| " Their low efficacy in controlling HZ pain and post-herpetic neuralgia development, and the need of multiple dosing regimens requiring daily dose adaptation for patients with renal failure urges the development of novel anti-VZV drugs." | ( Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Andrei, G; Snoeck, R, 2021) | 0.62 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 4 (57.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (14.29%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||